전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,045 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CorestaleRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 153Status Recruiting
AntibodyLimited DatastaleInnoventPhase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 152Status Recruiting
ADCLimited DatastaleDaiichi Sankyo Co., Ltd.Phase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 149Status Recruiting
AntibodyLimited DatastaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 148Status Active
ADCLimited DatastaleDaiichi Sankyo Co., Ltd.deruxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 148Status Recruiting
AntibodyCurated CorestaleJunshi BiosciencesPhase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 145Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 143Status Active
AntibodyLimited DatastalePENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#Popular#monoclonal-antibody+4
Trials 143Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleMerck KGaAPhase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 138Status Active
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 134Status Recruiting
ADCLimited DatastaleRochederuxtecan (Dato-DXd, Datro…Phase 3

T-DXd (Trastuzumab-Deruxtecan, Trastuzumab-Deruxtecan (T-DXd))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+3
Trials 134Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab (Camrelizumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 127Status Recruiting
AntibodyLimited DatastaleAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 127Status Recruiting
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan (T-DXd) with pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Approved#Popular#antibody-drug-conjugate+3
Trials 124Status Recruiting
AntibodyCurated CorestaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#BioJungboMoa-pick#Popular+5
Trials 123Status Recruiting
ADCLimited DatastaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 122Status Recruiting

5 / 103 pages

← PreviousNext →